Epidemiology & Biostatistics

The Ed Reznik Lab

Research

Ed Reznik, PhD

Assistant Professor

The Reznik Lab studies metabolic and mitochondrial dysfunction in cancer through analysis of multimodal genetic, metabolomic, and clinical data. We use computational tools to address a basic question: how do tumors adapt their metabolism, the process by which they obtain energy and nutrition from the extracellular environment, to sustain malignancy? Our research draws on data from basic science and clinical practice to understand how metabolic adaptations confer selective advantages to tumors, serve as biomarkers of response and resistance to therapy, and poise tumors for effective targeted intervention.

The lab’s research is equal parts machine learning, data science, and bioinformatics, and is conducted by a multidisciplinary group of quantitative scientists and translationally-minded physicians. We study metabolism in many disease contexts, but also have a unique translational focus on kidney cancer.

Featured News

MSK's Justin Jee, MD, PhD, and Ed Reznik, PhD, are seen smiling.

New Insights Into How Obesity Influences Cancer Driver Mutations

Learn about research at MSK that finds obesity can influence driver mutations that produce specific subtypes of cancers, including lung and endometrial cancers.

Publications Highlights

Xie AX, Tansey W*, Reznik E*. UnitedMet harnesses RNA-metabolite covariation to impute metabolite levels in clinical samples. Nat Cancer. 2025 Apr 18. doi: 10.1038/s43018-025-00943-0. Epub ahead of print. PMID: 40251399.

Zucker M, Perry MA, Gould SI, Elkrief A, Safonov A, Thummalapalli R, Mehine M, Chakravarty D, Brannon AR, Ladanyi M, Razavi P, Donoghue MTA, Murciano-Goroff YR, Grigoriadis K, McGranahan N, Jamal-Hanjani M, Swanton C, Chen Y, Shen R, Chandarlapaty S, Solit DB, Schultz N, Berger MF, Chang J, Schoenfeld AJ, Sánchez-Rivera FJ, Reznik E*, Bandlamudi C*. Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer. Cell. 2025 Feb 6;188(3):851-867.e17. doi: 10.1016/j.cell.2024.11.010. Epub 2024 Dec 18. PMID: 39701102; PMCID: PMC11922039.

Tang C, Castillon VJ, Waters M, Fong C, Park T, Boscenco S, Kim S, Pekala K, Carrot-Zhang J, Hakimi AA, Schultz N, Ostrovnaya I, Gusev A, Jee J*, Reznik E*. Obesity-dependent selection of driver mutations in cancer. Nat Genet. 2024 Nov;56(11):2318-2321. doi: 10.1038/s41588-024-01969-3. Epub 2024 Oct 28. PMID: 39468367; PMCID: PMC11549034.

Kim M, Gorelick AN, Vàzquez-García I, Williams MJ, Salehi S, Shi H, Weiner AC, Ceglia N, Funnell T, Park T, Boscenco S, O’Flanagan CH, Jiang H, Grewal D, Tang C, Rusk N, Gammage PA, McPherson A, Aparicio S, Shah SP*, Reznik E*. Single-cell mtDNA dynamics in tumors is driven by coregulation of nuclear and mitochondrial genomes. Nat Genet. 2024 May;56(5):889-899. doi: 10.1038/s41588-024-01724-8. Epub 2024 May 13. PMID: 38741018; PMCID: PMC11096122.

Mahmood M, Liu EM, Shergold AL, Tolla E, Tait-Mulder J, Huerta-Uribe A, Shokry E, Young AL, Lilla S, Kim M, Park T, Boscenco S, Manchon JL, Rodríguez-Antona C, Walters RC, Springett RJ, Blaza JN, Mitchell L, Blyth K, Zanivan S, Sumpton D, Roberts EW, Reznik E*, Gammage PA*. Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma. Nat Cancer. 2024 Apr;5(4):659-672. doi: 10.1038/s43018-023-00721-w. Epub 2024 Jan 29. PMID: 38286828; PMCID: PMC11056318.

View All Publications

People

Ed Reznik, PhD

Assistant Professor

The Reznik Lab studies metabolic and mitochondrial dysfunction in cancer through analysis of multimodal genetic, metabolomic, and clinical data.
PhD, Boston University